Bronchodilators, receptors and cross-talk: Together is better?

References

• Chapman KR , Mannino DM , Soriano JB , Vermeire PA , Buist AS , Thun MJ , et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188–207
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. Available from http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf. Last accessed 22 July 2015
   Google Scholar
• Patel JG , Nagar SP , Dalal AA . Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis 2014;9:289–300
   PubMed Web of Science ®Google Scholar
• Hanania NA , Donohue JF . Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 2007;4:526–34
   PubMedGoogle Scholar
• Montuschi P . Drugs for chronic obstructive pulmonary disease. Curr Med Chem 2013;20:1461–3
   PubMed Web of Science ®Google Scholar
• Montuschi P . Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2006;1:409–23
   PubMedGoogle Scholar
• Canning BJ , Fischer A . Neural regulation of airway smooth muscle tone. Respir Physiol 2001;125:113–27
   PubMedGoogle Scholar
• Canning BJ . Reflex regulation of airway smooth muscle tone. J Appl Physiol 2006;101:971–85
   PubMed Web of Science ®Google Scholar
• Tashkin DP , Ferguson GT . Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013;14:49
   PubMed Web of Science ®Google Scholar
• Montuschi P , Ciabattoni G . Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem 2015;58:4131–64
   PubMed Web of Science ®Google Scholar
• Cazzola M , Tashkin DP . Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009;6:404–15
   PubMedGoogle Scholar
• Barnes PJ . The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117:24S–32S
   PubMed Web of Science ®Google Scholar
• Cazzola M , Molimard M . The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257–67
   PubMed Web of Science ®Google Scholar
• Rhoden KJ , Meldrum LA , Barnes PJ . Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol (1985) 1988;65:700–5
   PubMed Web of Science ®Google Scholar
• Belmonte KE . Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:297–304
   PubMedGoogle Scholar
• Zhang X-Y , Olszewski MA , Robinson NE . Beta 2-adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves. Am J Physiol 1995;268:L950–6
   PubMed Web of Science ®Google Scholar
• Zhang X-Y , Zhu F-X , Olszewski MA , Robinson NE . Effects of enantiomers of β2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998;274:L32–8
   PubMed Web of Science ®Google Scholar
• Billington CK , Penn RB . Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res 2003;4:2
   PubMed Web of Science ®Google Scholar
• McGraw DW , Elwing JM , Fogel KM , Wang WC , Glinka CB , Mihlbachler KA , et al. Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. J Clin Invest 2007;117:1391–8
   PubMed Web of Science ®Google Scholar
• Dale PR , Cernecka H , Schmidt M , Dowling MR , Charlton SJ , Pieper MP , Michel MC . The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease. Curr Opin Pharmacol 2014;16:31–42
   PubMed Web of Science ®Google Scholar
• Pera T , Penn RB . Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol 2014;16:72–81
   PubMed Web of Science ®Google Scholar
• Schramm CM , Chuang ST , Grunstein MM . cAMP generation inhibits inositol 1,4,5-trisphosphate binding in rabbit tracheal smooth muscle. Am J Physiol 1995;269:L715–19
   PubMed Web of Science ®Google Scholar
• Yang C-M , Hsu M-C , Tsao H-L , Chiu C-T , Ong R , Hsieh J-T , Fan L-W . Effects of cAMP elevating agents on carbachol-induced phosphoinositide hydrolysis and calcium mobilization in cultured canine tracheal smooth muscle cells. Cell Calcium 1996;19:243–54
   PubMed Web of Science ®Google Scholar
• Roux E , Molimard M , Savineau J-P , Marthan R . Muscarinic stimulation of airway smooth muscle cells. Gen Pharmacol 1998;31:349–56
   PubMedGoogle Scholar
• Boterman M , Elzinga CRS , Wagemakers D , Eppens PB , Zaagsma J , Meurs H . Potentiation of β-adrenoceptor function in bovine tracheal smooth muscle by inhibition of protein kinase C. Eur J Pharmacol 2005;516:85–92
   PubMed Web of Science ®Google Scholar
• Kistemaker LEM , Oenema TA , Meurs H , Gosens R . Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci 2012;91:1126–33
   PubMed Web of Science ®Google Scholar
• Profita M , Bonanno A , Montalbano AM , Albano GD , Riccobono L , Siena L , et al. β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta 2012;1822:1079–89
   PubMed Web of Science ®Google Scholar
• Meurs H , Oenema TA , Kistemaker LEM , Gosens R . A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol 2013;13:316–23
   PubMed Web of Science ®Google Scholar
• Ohta S , Oda N , Yokoe T , Tanaka A , Yamamoto Y , Watanabe Y , et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy 2010;40:1266–75
   PubMed Web of Science ®Google Scholar
• Damera G , Jiang M , Zhao H , Fogle HW , Jester WF , Freire J , Panettieri RA Jr . Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation. Eur J Pharmacol 2010;649:349–53
   PubMed Web of Science ®Google Scholar
• Bos IS , Gosens R , Zuidhof AB , Schaafsma D , Halayko AJ , Meurs H , Zaagsma J . Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007;30:653–61
   PubMed Web of Science ®Google Scholar
• Vacca G , Randerath WJ , Gillissen A . Inhibition of granulocyte migration by tiotropium bromide. Respir Res 2011;12:24
   PubMed Web of Science ®Google Scholar
• Donnelly LE , Tudhope SJ , Fenwick PS , Barnes PJ . Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur Respir J 2010;36:178–86
   PubMed Web of Science ®Google Scholar
• Perng D-W , Su K-C , Chou K-T , Wu Y-C , Chen C-S , Hsiao Y-H , et al. Long-acting β2 agonists and corticosteroids restore the reduction of histone deacetylase activity and inhibit H2O2-induced mediator release from alveolar macrophages. Pulm Pharmacol Ther 2012;25:312–18
   PubMed Web of Science ®Google Scholar
• Shen L-L , Liu Y-N , Shen H-J , Wen C , Jia Y-L , Dong X-W , et al. Inhalation of glycopyrronium inhibits cigarette smoke-induced acute lung inflammation in a murine model of COPD. Int Immunopharmacol 2014;18:358–64
   PubMed Web of Science ®Google Scholar
• Teixeira MM , Williams TJ , Hellewell PG . Anti-inflammatory effects of a short-acting and a long-acting β2-adrenoceptor agonist in guinea pig skin. Eur J Pharmacol 1995;272:185–93
   PubMed Web of Science ®Google Scholar
• Whelan CJ , Johnson M , Vardey CJ . Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 1993;110:613–18
   PubMed Web of Science ®Google Scholar
• Cazzola M , Calzetta L , Matera MG . β2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4–17
   PubMed Web of Science ®Google Scholar
• Hanania NA , Moore RH . Anti-inflammatory activities of β2-agonists. Curr Drug Targets Inflamm Allergy 2004;3:271–7
   PubMedGoogle Scholar
• Theron AJ , Steel HC , Tintinger GR , Feldman C , Anderson R . Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting? Drug Des Devel Ther 2013;7:1387–98
   PubMed Web of Science ®Google Scholar
• Costa L , Roth M , Miglino N , Keglowich L , Zhong J , Lardinois D , et al. Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway. Pulm Pharmacol Ther 2014;27:29–37
   PubMed Web of Science ®Google Scholar
• Sindi A , Todd DC , Nair P . Antiinflammatory effects of long-acting β2-agonists in patients with asthma: a systematic review and metaanalysis. Chest 2009;136:145–54
   PubMed Web of Science ®Google Scholar
• Matera MG , Page CP , Cazzola M . Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495–506
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2015. Available from http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf. Last accessed 1 July 2015
   Google Scholar
• Bateman ED , Mahler DA , Vogelmeier CF , Wedzicha JA , Patalano F , Banerji D . Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014;8:357–79
   PubMed Web of Science ®Google Scholar
• Calzetta L , Matera MG , Cazzola M . Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol 2015;761:168–73
   PubMed Web of Science ®Google Scholar
• Cazzola M , Calzetta L , Segreti A , Facciolo F , Rogliani P , Matera MG . Translational study searching for synergy between glycopyrronium and indacaterol. COPD 2015;12:175–81
   PubMedGoogle Scholar
• Wang J , Jin D , Zuo P , Wang T , Xu Y , Xiong W . Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2011;16:350–8
   PubMed Web of Science ®Google Scholar
• Mahler DA , D’Urzo A , Bateman ED , Ozkan SA , White T , Peckitt C , et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781–8
   PubMed Web of Science ®Google Scholar
• Van Noord JA , Aumann J-L , Janssens E , Smeets JJ , Zaagsma J , Mueller A , Cornelissen PJ . Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010;104:995–1004
   PubMed Web of Science ®Google Scholar
• Aaron SD , Vandemheen KL , Fergusson D , Maltais F , Bourbeau J , Goldstein R , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545–55
   PubMed Web of Science ®Google Scholar
• Beier J , van Noord J , Deans A , Brooks J , Maden C , Baggen S , et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Int J Chron Obstruct Pulmon Dis 2012;7:153–64
   PubMed Web of Science ®Google Scholar
• ZuWallack R , Allen L , Hernandez G , Ting N , Abrahams R . Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis 2014;9:1133–44
   PubMed Web of Science ®Google Scholar
• Frampton JE . QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014;74:465–88
   PubMed Web of Science ®Google Scholar
• Cazzola M , Segreti A , Matera MG . New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther 2013;7:1201–8
   PubMed Web of Science ®Google Scholar
• Feldman GJ , Edin A . The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis 2013;7:311–19
   PubMedGoogle Scholar
• Kelly E . Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol 2014;7:403–13
   PubMed Web of Science ®Google Scholar
• Montuschi P , Macagno F , Valente S , Fuso L . Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem 2013;20:1464–76
   PubMed Web of Science ®Google Scholar
• Fuso L , Mores N , Valente S , Malerba M , Montuschi P . Long-acting beta-agonists and their association with inhaled corticosteroids in COPD. Curr Med Chem 2013;20:1477–95
   PubMed Web of Science ®Google Scholar
• Malerba M , Morjaria JB , Radaeli A . Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis 2014;9:687–95
   PubMed Web of Science ®Google Scholar
• Bateman ED , Ferguson GT , Barnes N , Gallagher N , Green Y , Henley M , Banerji D . Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484–94
   PubMed Web of Science ®Google Scholar
• Beeh K-M , Westerman J , Kirsten A-M , Hébert J , Grönke L , Hamilton A , et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015;32:53–9
   PubMed Web of Science ®Google Scholar
• Buhl R , Maltais F , Abrahams R , Bjermer L , Derom E , Ferguson G , et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J 2015;45:969–79
   PubMed Web of Science ®Google Scholar
• Celli B , Crater G , Kilbride S , Mehta R , Tabberer M , Kalberg CJ , Church A . Once-daily umeclidinium/vilanterol 125/25 μg in COPD. A randomized, controlled study. Chest 2014;145:981–91
   PubMed Web of Science ®Google Scholar
• Decramer M , Anzueto A , Kerwin E , Kaelin T , Richard N , Crater G , et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014;2:472–86
   PubMed Web of Science ®Google Scholar
• Donohue JF , Maleki-Yazdi MR , Kilbride S , Mehta R , Kalberg C , Church A . Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538–46
   PubMed Web of Science ®Google Scholar
• Mahler DA , Decramer M , D’Urzo A , Worth H , White T , Alagappan VK , et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014;43:1599–609
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR , Kaelin T , Richard N , Zvarich M , Church A . Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014;108:1752–60
   PubMed Web of Science ®Google Scholar
• van Noord JA , Buhl R , LaForce C , Martin C , Jones F , Dolker M , Overend T . QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010;65:1086–91
   PubMed Web of Science ®Google Scholar
• Dahl R , Jadayel D , Alagappan VKT , Chen H , Banerji D . Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501–8
   PubMed Web of Science ®Google Scholar
• van der Molen T , Cazzola M . Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101–8
   PubMedGoogle Scholar
• Wedzicha JA , Decramer M , Ficker JH , Niewoehner DE , Sandström T , Fowler Taylor A , et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199–209
   PubMed Web of Science ®Google Scholar
• Buhl R , Gessner C , Schuermann W , Foerster K , Sieder C , Hiltl S , Korn S . Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 2015;70:311–19
   PubMed Web of Science ®Google Scholar
• Wedzicha JA , Dahl R , Buhl R , Schubert-Tennigkeit A , Chen H , D’Andrea P , et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014;108:1498–507
   PubMed Web of Science ®Google Scholar
• Dahl R , Chapman KR , Rudolf M , Mehta R , Kho P , Alagappan VK , et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respir Med 2013;107:1558–67
   PubMed Web of Science ®Google Scholar
• Donohue JF , Niewoehner D , Brooks J , O’Dell D , Church A . Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014;15:78
   PubMed Web of Science ®Google Scholar
• Feldman G , Walker RR , Brooks J , Mehta R , Crater G . 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2012;25:465–71
   PubMed Web of Science ®Google Scholar
• Drollmann A , Brown M , Sechaud R , Perry S , Hara H , Jones I , Febbraro S . Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers. Int J Clin Pharmacol Ther 2014;52:369–80
   PubMed Web of Science ®Google Scholar
• Van de Maele B , Fabbri LM , Martin C , Horton R , Dolker M , Overend T . Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 2010;7:418–27
   PubMedGoogle Scholar
• Global Initiative for Asthma, Global Initiative for Chronic Obstructive Lung Disease . Diagnosis of diseases of chronic airflow limitation: asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). Available from http://www.ginasthma.org/local/uploads/files/AsthmaCOPDOverlap.pdf. Last accessed 24 February 2015
   Google Scholar
• Andersén H , Lampela P , Nevanlinna A , Säynäjäkangas O , Keistinen T . High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J 2013;7:342–6
   PubMed Web of Science ®Google Scholar
• Montuschi P , Malerba M , Santini G , Miravitlles M . Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today 2014;19:1928–35
   PubMed Web of Science ®Google Scholar
• Nelson HS , Weiss ST , Bleecker ER , Yancey SW , Dorinsky PM . The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15–26
   PubMed Web of Science ®Google Scholar
• Bell AD , McIvor RA . The SMART study. Can Fam Physician 2007;53:687–8
   PubMed Web of Science ®Google Scholar
• Lipworth BJ . Emerging role of long acting muscarinic antagonists for asthma. Br J Clin Pharmacol 2014;77:55–62
   PubMed Web of Science ®Google Scholar
• Cazzola M , Page C , Matera MG . Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26:307–17
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM , Casale TB , Bleecker ER , Meltzer EO , Pizzichini E , Schmidt O , et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med 2015;3:367–76
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM , Engel M , Dahl R , Paggiaro P , Beck E , Vandewalker M , et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198–207
   PubMed Web of Science ®Google Scholar
• Price D , West D , Brusselle G , Gruffydd-Jones K , Jones R , Miravitlles M , et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014;9:889–905
   PubMed Web of Science ®Google Scholar
• Wielders PLML , Ludwig-Sengpiel A , Locantore N , Baggen S , Chan R , Riley JH . A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 2013;42:972–81
   PubMed Web of Science ®Google Scholar
• Bateman ED , Kornmann O , Ambery C , Norris V . Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013;26:581–7
   PubMed Web of Science ®Google Scholar
• Cazzola M , Lopez-Campos J-L , Puente-Maestu L . The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J 2013;42:885–7
   PubMed Web of Science ®Google Scholar
• Malerba M , Montuschi P , Radaeli A , Pirisi M . Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today 2015;20:129–35
   PubMed Web of Science ®Google Scholar